Imeik Technology Development Co.,Ltd.

Equities

300896

CNE100004868

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-14 pm EDT 5-day change 1st Jan Change
294.7 CNY +1.67% Intraday chart for Imeik Technology Development Co.,Ltd. +1.46% +0.13%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Imeik Technology Development's Profit Rises 47% on Higher Revenue MT
Imeik Technology Development Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Imeik Technology Development Co.,Ltd.'s Equity Buyback Plan announced on June 12, 2023. CI
Imeik Technology Development Co.,Ltd.'s Equity Buyback announced on June 12, 2023, has closed with 1,165,874 shares, representing 0.54% for CNY 399.69 million. CI
QL Biopharmaceutical announced that it has received CNY 200 million in funding from BlueRun Investment Consulting Co., Ltd., Imeik Technology Development Co.,Ltd., China-US Green Fund Management Co., Ltd., Shenzhen Jiayuan Capital Management Co., Ltd., Chengdu Science and Technology Innovation Investment Group Co., Ltd., Shanghai Jincheng Equity Investment Fund Management Co., Ltd. and other investors CI
Imeik Technology Wins Exclusive Rights to Distribute Jeisys’ Aesthetic Equipment in China MT
Imeik Technology Development Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tranche Update on Imeik Technology Development Co.,Ltd.'s Equity Buyback Plan announced on June 12, 2023. CI
Imeik Technology Development's Profit Jumps 65.7% in H1 MT
Imeik Technology Development Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tranche Update on Imeik Technology Development Co.,Ltd.'s Equity Buyback Plan announced on June 12, 2023. CI
Imeik Technology Development Co.,Ltd. announces an Equity Buyback for CNY 400 million worth of its shares. CI
Imeik Technology Development Co.,Ltd. authorizes a Buyback Plan. CI
Imeik Technology Development Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Imeik Technology’s Profit Jumps 32% as Revenue Rises 34% in 2022 MT
Imeik Technology Development Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Imeik Technology Development Co.,Ltd. Approves Director Appointments CI
Imeik Technology’s Profit Jumps 42% as Revenue Rises 55% in Q3 MT
Imeik Technology Development Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
UBS Adjusts Imeik Technology Development's Price Target to 605.46 Yuan From 617.23 Yuan, Keeps at Neutral MT
Imeik Technology Posts Double-Digit Earnings Growth in H1 Despite COVID-19 Disruptions; Shares Rise 3% MT
Imeik Technology Development Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
UBS Starts Imeik Technology Development at 617.23 Yuan Price Target MT
Imeik Technology Development Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Beijing Nuobote Biotech Co., Ltd. announced that it expects to receive CNY 56 million in funding from Imeik Technology Development Co.,Ltd. CI
Chart Imeik Technology Development Co.,Ltd.
More charts
Imeik Technology Development Co Ltd is a China-based company mainly engaged in the research and development, production and sales of biomedical materials. The Company focuses on the development and transformation of biomedical materials, and is committed to the development of biomedicine such as recombinant proteins and peptides. The Company has realized the industrialization of injection-type sodium hyaluronate series products and polydioxanone facial implants, and has established a product technology transformation platform for biomedical materials such as medical chitosan and polylactic acid. The Company's self-developed products are mainly aimed at the repair of fold skin on the face and neck. The clinical applications of its products cover medical cosmetology, surgical repair, and treatment of metabolic diseases. The Company mainly conducts its businesses in the China market.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
294.7 CNY
Average target price
449.3 CNY
Spread / Average Target
+52.45%
Consensus
  1. Stock Market
  2. Equities
  3. 300896 Stock
  4. News Imeik Technology Development Co.,Ltd.
  5. Imeik Technology Trims 2021 Dividend Despite Robust Full-Year Earnings